Could CSL shares capitalise on the next pandemic?

While CSL didn't see its share price explode like some vaccine makers, the company was hard at work to combat the coronavirus.

| More on:
woman getting the Covid 19 vaccine

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • CSL shares gained global attention amid the COVID pandemic
  • CSL Seqirus has been contracted to deliver an avian flu vaccine candidate for a clinical study in the United States
  • The company’s US-based Holly Springs facility is prepared to make 150 million vaccine doses within the first six months of an outbreak

CSL Limited (ASX: CSL) shares weren't immune to the initial stock market panic that unfolded in the face of the COVID-19 pandemic.

In the month-long sell-off from late February 2020 through to late March 2020, the S&P/ASX 200 Index (ASX: XJO) global biotech company fell by some 20%.

Over the following month, CSL shares quickly recouped those losses.

While CSL didn't see its share price explode like some vaccine makers, the company was hard at work to combat the coronavirus.

In an agreement with AstraZeneca, CSL committed to manufacturing around 50 million doses of vaccines in Australia for domestic supply. The first doses were delivered in March 2021.

Which begs the question, could CSL shares capitalise on the next pandemic?

What's this about the avian flu?

Before ploughing ahead, our apologies for even throwing out the words 'next pandemic'. There's no need to go hoarding toilet paper and long-life milk just yet. Or hopefully ever again!

But that doesn't mean governments and biotech firms aren't working to get ahead of any potential future outbreaks.

As Fierce Pharma reports, CSL Seqirus – a subsidiary of CSL – inked a $30.1 million agreement with the Biomedical Advanced Research and Development Authority (BARDA), a branch of the United States Department of Health and Human Services.

The agreement will see CSL deliver an avian flu vaccine candidate for a clinical study.

There have only been a few reported cases of the avian flu being transmitted from a bird to a person. And no reported cases of human-to-human transmission yet.

However, Lorna Meldrum, VP of commercial operations, international and pandemic response at CSL Seqirus, said BARDA is concerned enough about the potential dangers of the avian flu to fund the research.

"The next pandemic is probably going to be an influenza pandemic," Meldrum said. She noted that CSL Seqirus has partnerships with BARDA and other government health agencies across the globe.

Meldrum said that if there was another pandemic outbreak, CSL's seasonal flu shot production at its Holly Springs plant in North Carolina would "immediately switch" over to producing the pandemic influenza vaccine. She said the plant would be prepared to make 150 million doses within the first six months.

Addressing the company's readiness at its Holly Springs facility, Meldrum said (quoted by Fierce Pharma):

We have all the ingredients that you need to make a flu vaccine. We have a trained workforce. We have all our [standard operating procedures] in line; we have all our regulatory documents. So, we're like a machine that you just flick the switch, and then we're up and running.

How have CSL shares been performing?

The CSL share price has slipped 6.3% in 2022. That compares to a year-to-date loss of 12.4% posted by the ASX 200.

Longer-term, CSL shares are up 101% over five years.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Up 29% this year, does Macquarie expect Medibank Private shares to continue rising?

Medibank's explosive share price growth has caught the eye of this broker.

Read more »

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »